ScoreComparison
Why is Amicus Therapeutics, Inc. ?
1
With a growth in Net Profit of 55.57%, the company declared Very Positive results in Jun 25
- The company has declared positive results for the last 6 consecutive quarters
- NET PROFIT(HY) Higher at USD -44.4 MM
- ROCE(HY) Highest at -22.62%
- RAW MATERIAL COST(Y) Fallen by 0.48% (YoY)
2
Market Beating Performance
- The stock has generated a return of 44.41% in the last 1 year, much higher than market (S&P 500) returns of 15.98%
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Amicus Therapeutics, Inc. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Amicus Therapeutics, Inc. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Amicus Therapeutics, Inc.
-100.0%
0.83
50.08%
S&P 500
13.66%
0.81
19.85%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
20.27%
EBIT Growth (5y)
15.91%
EBIT to Interest (avg)
-4.28
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.77
Sales to Capital Employed (avg)
0.83
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.79%
ROE (avg)
0
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
9.80
EV to EBIT
42.80
EV to EBITDA
36.52
EV to Capital Employed
5.98
EV to Sales
3.77
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
13.96%
ROE (Latest)
-13.55%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Bullish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend9What is working for the Company
NET PROFIT(HY)
Higher at USD -44.4 MM
ROCE(HY)
Highest at -22.62%
RAW MATERIAL COST(Y)
Fallen by 0.48% (YoY
NET SALES(Q)
Highest at USD 154.69 MM
-11What is not working for the Company
PRE-TAX PROFIT(Q)
At USD -17.48 MM has Fallen at -16,284.26%
INVENTORY TURNOVER RATIO(HY)
Lowest at 0.53 times
CASH AND EQV(HY)
Lowest at USD 481.57 MM
NET PROFIT(Q)
Lowest at USD -22.72 MM
EPS(Q)
Lowest at USD -0.08
Here's what is working for Amicus Therapeutics, Inc.
Net Sales
Highest at USD 154.69 MM
in the last five periodsMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Raw Material Cost
Fallen by 0.48% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin
Raw Material Cost as a percentage of Sales
Here's what is not working for Amicus Therapeutics, Inc.
Pre-Tax Profit
At USD -17.48 MM has Fallen at -16,284.26%
Year on Year (YoY)MOJO Watch
Near term Pre-Tax Profit trend is very negative
Pre-Tax Profit (USD MM)
Net Profit
At USD -22.72 MM has Fallen at -44.73%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is very negative
Net Profit (USD MM)
Inventory Turnover Ratio
Lowest at 0.53 times and Fallen
In each half year in the last five Semi-Annual periodsMOJO Watch
Company's pace of selling inventory has slowed
Inventory Turnover Ratio
Net Profit
Lowest at USD -22.72 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is negative
Net Profit (USD MM)
EPS
Lowest at USD -0.08
in the last five periodsMOJO Watch
Declining profitability; company has created lower earnings for shareholders
EPS (USD)
Cash and Eqv
Lowest at USD 481.57 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is deteriorating
Cash and Cash Equivalents
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
